Navigation Links
UCLA, Caltech research on immune-cell therapy could strengthen promising melanoma treatment
Date:3/22/2013

A new study of genetically modified immune cells by scientists from UCLA and the California Institute of Technology could help improve a promising treatment for melanoma, an often fatal form of skin cancer.

The research, which appears March 21 in the advance online edition of the journal Cancer Discovery, was led by James Heath, a member of UCLA's Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research and UCLA's Jonsson Comprehensive Cancer Center. Heath is a professor of molecular and medical pharmacology at UCLA and also holds the Elizabeth W. Gilloon Chair in Chemistry at Caltech.

The melanoma treatment uses T cells immune cells that play a major role in fighting infection taken from patients with melanoma. The cells are then genetically modified in the laboratory so that when they are reintroduced into a patient's bloodstream, they specifically attack melanoma tumors. In early clinical trials, this treatment was shown to shrink tumors dramatically in many patients, but the positive effects were often short-lived.

The UCLA and Caltech researchers found that after the engineered T cells were returned to patients, their efficacy faded within two to three weeks. Surprisingly, however, once the engineered cells were no longer effective, a new group of non-engineered T cells arose that had a similar tumor-killing effect that lasted even longer, the scientists discovered.

Using newly developed nanotechnology chips to perform multidimensional and multiplexed immune-monitoring assays, the researchers were able to examine at high resolution single engineered T cells taken at different times from patients undergoing the therapy, each of whom had a different level of response to the treatment.

"The engineered T cells did not recover their tumor-killing effect," Heath said, "but after one month, another group of T cells appeared that did have tumor-killing effects for another 90 days. Those were not the genetically engineered T cells, and they appeared to be a byproduct of a process called 'antigen spreading' by the original engineered cells. After 90 days, those cells lost their tumor-killing ability as well."

Antigen spreading is a process by which a T cell that has been engineered to attack a particular tumor expands its immune response to other T cells in the body, which then attack the same tumor but are focused on different antigens. (Antigens are substances that trigger a response by the body's immune system.) Scientists may be able to use this process, Heath stressed, to improve T cellbased treatments for melanoma.

"Our results have led us to possible ways to improve the T cell therapy to extend its positive effect," Heath said. "We need to incorporate strategies that maintain the functional properties of the engineered T cells used for therapy. This might include modifying how we grow the T cells in the laboratory to make their tumor-killing effect last longer or make them resistant to the effects of the patient's T cells as they recover from pretreatment chemotherapy conditioning and possibly increase the antigen spreading of anti-tumor T cells."

UCLA professor of medicine Dr. Antoni Ribas was one of Heath's key collaborators on the research.

"One of the possible approaches to resolve the problem identified by this study is to use engineered blood stem cells instead of the peripheral blood used in the original trials with this therapy in the hope that the engineered blood stem cells will provide a renewable source of engineered T cells," said Ribas, a member of UCLA's Broad Stem Cell Research Center and Jonsson Cancer Center.

Caltech's Chao Ma, the study's first author, said the findings and the use of the new nanotechnology assay process hold promise for treatments of other disease as well.

"This study points to the value of these single-cell functional analyses for probing the successes and failures of a sophisticated immunotherapy," he said. "I am excited to see its use as a monitoring tool to understand a spectrum of other cellular immunotherapies in the near future."


'/>"/>

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Scientists from UCLA, Israels Technion uncover brains code for pronouncing vowels
2. Michigan Lupus Foundation Texas Hold 'Em Tournament Raises Thousands for Lupus Support, Education & Research
3. Frisco Institute for Reproductive Medicine Welcomes China Research Team
4. Research explores links between physical and emotional pain relief
5. Multiple sclerosis research: The thalamus moves into the spotlight
6. Dr. Roger D. Weiss earns Hazeldens Dan Anderson Research Award
7. Patient Wishes Should Guide End-of-Life Care, Researchers Say
8. Scripps Research study underlines potential of new technology to diagnose disease
9. Researchers new method may sharpen microscopic images
10. New web portal on health research in Europe
11. Researchers tackle physician challenge of correctly ordering laboratory tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Natural Subsistence, ... aspects of people’s health and nutrition, announced its product Leyzene is now available ... Subsistence develops nutritional supplements that help people improve all aspects of their health ...
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of ... the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management and Patient ... contributed not only to the association, but also to the Health Care Quality and ...
(Date:3/23/2017)... , ... March 23, 2017 ... ... Complying with European Guidelines and the New MEDDEV 2.7/1 Rev. 4 Guidance, ... ET, http://www.fdanews.com/mdclineval                  , How will the new EU MDR language ...
(Date:3/23/2017)... ... ... and Back”: a true-life testimony of tragedy and the miraculous power of God to ... mother and grandmother committed to sharing her many spiritual adventures which affirm God’s grace ... actual events in the life of her family, which validate her deep faith in ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful Response To ... Response To Atheist Manifesto” is the creation of published author Richard Hostetter, a ... sixty years. He holds graduate degrees from Kent State University and the University ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 2017 ReNeuron reported in December 2016 ... chronic stroke patients, despite not meeting the three-month time frame ... Action Research Arm Test (ARAT). As a result, the company ... clinical study in 2017. Beyond CTX, we expect safety and ... and Phase I data from its critical limb ischaemia (CLI) ...
(Date:3/22/2017)... -- ReportsnReports.com adds Global Vagus Nerve Stimulation ... global vagus nerve stimulation market analyst says one trend ... invasive VNS procedures. Few years ago, VNS procedures were ... high standards of healthcare infrastructure. ... Browse 30 Exhibits, ...
(Date:3/22/2017)... , March 22, 2017 Ampio ... the development of Ampion™, a low molecular weight ... today announced that it is re-issuing its previous release ... incorporate certain disclosures that are required under the ... below are these additional disclosures along with the ...
Breaking Medicine Technology: